Rallybio CORP Form 4 insider transactions

Rallybio Corporation announced a definitive agreement to acquire Avenzo Therapeutics, Inc., a clinical-stage oncology company, for an undisclosed sum, alongside a concurrent $215 million private placement financing.

ADAR1 Capital Management, LLC reported the acquisition of 16,209 shares of Rallybio Corp common stock across multiple transactions.

ADAR1 Capital Management, LLC reported the acquisition of 79,559 shares of Rallybio Corp common stock between May 13 and May 15, 2026.

ADAR1 Capital Management, LLC and Daniel Schneeberger have increased their beneficial ownership in Rallybio Corp through recent open market purchases.

ADAR1 Capital Management and Daniel Schneeberger acquired 155,905 shares of Rallybio Corp, signaling strong institutional confidence.

Rallybio Corporation will acquire clinical-stage Candid Therapeutics in a merger, backed by over $505 million in new financing, to advance a T-cell engager pipeline for autoimmune diseases.

Rallybio's Chief Financial Officer, Jonathan I Lieber, reported recent acquisitions and sales of company common stock, primarily for tax obligations.

Rallybio Corporation's Director Martin Mackay was granted 18,055 stock options in lieu of $65,000 in retainer fees, vesting monthly through 2026.

Rallybio Corp Director Ronald Hunt acquired 14,305 stock options with an exercise price of $4.45, vesting monthly through 2026.

Director Helen M Boudreau reports the grant of stock options in Rallybio Corp.

Director Wendy Chung acquired options to purchase 28,500 shares of Rallybio Corp common stock on May 13, 2025.

Director Ronald Hunt acquired options to purchase 28,500 shares of Rallybio Corp stock on May 13, 2025, according to a Form 4 filing.

Christine A. Nash, a director of Rallybio Corp, reports the acquisition of options to purchase 28,500 shares of common stock.

Robert Lorne Hopfner, a director of Rallybio Corp, reports the acquisition of options to purchase 28,500 shares of common stock.

Paula Soteropoulos, a director at Rallybio Corp, reports the acquisition of options to purchase 28,500 shares of common stock.

Director Liu Hui of Rallybio Corp. was granted stock options for 28,500 shares on May 13, 2025, according to a Form 4 filing.

Martin Mackay, a director at Rallybio Corp, reports the acquisition of options to purchase 28,500 shares of common stock.

Stephen Uden, CEO of Rallybio Corp, reports the acquisition of 453,700 stock options on February 14, 2025, according to a Form 4 filing.

Steven Ryder, Chief Medical Officer of Rallybio Corp, reports the acquisition of 180,000 options in the company's stock.

Jonathan Lieber, CFO of Rallybio Corp, reports the acquisition of 180,000 stock options on February 14, 2025.

Rallybio director Martin Mackay acquired options for 92,857 shares of common stock in lieu of $65,000 in retainer fees.

Director Ronald Hunt acquired options to purchase 73,571 shares of Rallybio Corp common stock in lieu of retainer fees.

Director Robert Lorne Hopfner acquired options to purchase 73,571 shares of Rallybio Corp common stock on January 2, 2025, in lieu of $51,500 in retainer fees.

Director Liu Hui of Rallybio Corp acquires options for common stock in lieu of retainer fees, according to a Form 4 filing.

Director Ronald Hunt acquired options to purchase 16,500 shares of Rallybio Corp common stock on May 15, 2024.

Director Helen M Boudreau acquired options to purchase 16,500 shares of Rallybio Corp common stock on May 15, 2024.

Director Liu Hui acquired options to purchase 16,500 shares of Rallybio Corp stock on May 15, 2024.

Director Kush Parmar acquired options to purchase 16,500 shares of Rallybio Corp common stock at an exercise price of $1.91 on May 15, 2024.

Director Paula Soteropoulos acquired options to purchase 16,500 shares of Rallybio Corp common stock on May 15, 2024.

Christine A. Nash, a director of Rallybio Corp, reports the acquisition of options to purchase 16,500 shares of common stock.